A tracheal scaffold and bioreactor system manufactured by Holliston-based Harvard Bioscience were used in the first successful transplant of a regenerated trachea in the United States, the company announced.
Holliston-based Harvard Bioscience (HBIO) said it will delay an initial public offering of its subsidiary, Harvard Apparatus Regenerative Technology (HART), because of market conditions.